Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis

中文摘要

本研究旨在評估批地樂普眼科溶液(lotilaner ophthalmic solution) 0.25%與對照組的安全性和有效性。研究對象為412名患有睫毛蠕形蟲性眼瞼炎的患者，隨機分配到兩組中。結果顯示，批地樂普組的蠕形蟲密度顯著降低，且治療組在蠕形蟲根除率方面優於對照組。六週每日兩次使用批地樂普眼科溶液0.25%治療對於蠕形蟲性眼瞼炎的有效性被證實，在安全性方面也沒有出現顯著不良事件。因此，批地樂普眼科溶液0.25%可以作為蠕形蟲性眼瞼炎的治療選擇。另紅腫(erythema)治癒率似乎在與細胞皮(collarette) 以及蟎蟲根除(mite eradication)相比的後期時間點達到高峰。研究提出假設，消除或解決蟎蟲和細胞皮後，炎症需要一定的時間才能緩解。

English Abstract

The content is a summary of a study evaluating the safety and effectiveness of lotilaner ophthalmic solution 0.25% (bid x 6 weeks) for the treatment of Demodex blepharitis. Lotilaner is an antiparasitic agent that targets Demodex mites, which infest the eyelash follicles and can cause damage. The study involved 412 patients who were randomly assigned to receive either lotilaner or a placebo. Mite density was measured as the number of mites per lash. The study found that the lotilaner group had significantly lower mite density and a higher proportion of patients achieving mite eradication compared to the placebo group. The study found significant differences between the study group and the control group by week 2, with the rate of erythema cure peaking at later time points compared to collarette and mite eradication. The treatment was well-tolerated with no clinically significant adverse effects observed. Overall, the study concluded that lotilaner ophthalmic solution 0.25% is an effective treatment for Demodex blepharitis. The study concluded that it may take time for inflammation to resolve after mites and collarettes have been eradicated